Mizuho Securities analyst Uy Ear maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 46.0% and a total average return of 5.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Sarepta experienced a significant third-quarter performance surpassing expectations in terms of overall and Elevidys revenue. The company's consistent guidance for Elevidys seems to err on the side of caution.
Sales of Elevidys and the exon-skipping franchise surpassed consensus expectations, and the management's outlook for Q4 Elevidys remains intact, which may set the stage for further success barring significant holiday disruptions. There's anticipation for a possible increase to the FY25 guidance come January, though current market valuations reflect a perspective that views the franchise through a five-year lens leading up to the loss of exclusivity.
Sarepta's product, Elevidys, exhibited sales growth in the third quarter that surpassed expectations, accompanied by optimistic remarks from management regarding the product's market introduction. All indications suggest that Elevidys has the potential to evolve into a product generating several billions in sales, which could be further enhanced by a series of gene therapy debuts anticipated over the forthcoming five years.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞穗證券分析師Uy Ear維持$Sarepta Therapeutics (SRPT.US)$買入評級。
根據TipRanks數據顯示，該分析師近一年總勝率為46.0%，總平均回報率為5.0%。
此外，綜合報道，$Sarepta Therapeutics (SRPT.US)$近期主要分析師觀點如下：
Sarepta在第三季度的表現顯著超過了整體和Elevidys營業收入的預期。該公司對Elevidys的持續指導似乎更加謹慎。
Elevidys和外顯子跳躍特許權的銷售超出共識預期，管理層對Q4 Elevidys的展望保持完整，這可能爲進一步成功鋪平道路，除非有重大假日干擾。人們期待一月份的FY25指引可能會有所增加，儘管當前市場估值反映了一個將該特許權視作爲五年視角直至獨家權利喪失的觀點。
Sarepta的產品Elevidys在第三季度的銷售增長超出預期，管理層對產品的市場介紹發表了樂觀的言論。所有跡象表明，Elevidys有潛力成爲一個創造數十億銷售額的產品，這可能會被預期在未來五年推出的一系列基因療法的首次亮相進一步提升。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
